Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan 1;9(1):e2017002.
doi: 10.4084/MJHID.2017.002. eCollection 2017.

Antibacterial Resistance in Patients with Hematopoietic Stem Cell Transplantation

Sehnaz Alp  1 , Murat Akova  2
Affiliations
Review

Antibacterial Resistance in Patients with Hematopoietic Stem Cell Transplantation

Sehnaz Alp et al. Mediterr J Hematol Infect Dis. .

Abstract

Recipients of hematopoietic stem cell transplantation (HSCT) are at substantial risk of bacterial, fungal, viral, and parasitic infections depending on the time elapsed since transplantation, presence of graft-versus-host disease (GVHD), and the degree of immunosuppression. Infectious complications in HSCT recipients are associated with high morbidity and mortality. Bacterial infections constitute the major cause of infectious complications, especially in the early post-transplant period. The emergence of antibacterial resistance complicates the management of bacterial infections in this patient group. Multidrug-resistant bacterial infections in this group of patients have attracted considerable interest and may lead to significant morbidity and mortality. Empirical antibacterial therapy in patients with HSCT and febrile neutropenia has a critical role for survival and should be based on local epidemiology. This review attempts to provide an overview of risk factors and epidemiology of emerging resistant bacterial infections and their management in HSCT recipients.

Keywords: Hematopoietic stem cell transplantation; antibacterial resistance; resistant bacterial infection.

PubMed Disclaimer

References

    1. Giralt S. Allogeneic hematopoietic progenitor cell transplantation for the treatment of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors: lessons learned to date. Clin Lymphoma Myeloma. 2007;7(Suppl 3):S102–4. https://doi.org/10.3816/CLM.2007.s.009. - DOI - PubMed
    1. Dreger P, Corradini P, Kimby E, et al. Chronic Leukemia Working Party of the EBMT. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia. 2007;21:12–7. https://doi.org/10.1038/sj.leu.2404441. - DOI - PubMed
    1. Davies JK, Guinan EC. An update on the management of severe idiopathic aplastic anaemia in children. Br J Haematol. 2007;136:549–64. https://doi.org/10.1111/j.1365-2141.2006.06461.x. - DOI - PubMed
    1. Mackall C, Fry T, Gress R, Peggs K, Storek J, Toubert A. Background to hematopoietic cell transplantation, including post transplant immune recovery. Bone Marrow Transplant. 2009;44:457–62. https://doi.org/10.1038/bmt.2009.255. - DOI - PubMed
    1. Meijer E, Dekker AW, Lokhorst HM, Petersen EJ, Nieuwenhuis HK, Verdonck LF. Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation. Transpl Infect Dis. 2004;6:171–8. https://doi.org/10.1111/j.1399-3062.2004.00075.x. - DOI - PubMed